NLS Pharmaceutics (NLSP) News Today $1.95 -0.10 (-4.88%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.94 0.00 (-0.26%) As of 02/21/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period NLS Pharmaceutics files $75M mixed securities shelfFebruary 11, 2025 | markets.businessinsider.comNLS and Kadimastem to merge, aim for diabetes care innovationFebruary 10, 2025 | msn.comNLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 TherapiesFebruary 10, 2025 | prnewswire.comNLS Pharmaceutics files to sell 645,161 common shares for holdersFebruary 5, 2025 | markets.businessinsider.comKadimastem Ltd.: Kadimastem Shareholders Approved the Merger with NLS PharmaceuticsJanuary 31, 2025 | finanznachrichten.deNLS Pharmaceutics’ merger approved by Kadimastem shareholdersJanuary 31, 2025 | markets.businessinsider.comNLS Gains on Deal with KardimastemJanuary 31, 2025 | baystreet.caNLS and Kadimastem move forward with merger plansJanuary 31, 2025 | msn.comNLS Pharmaceutics Stock Rises 29% Following Merger Announcement With KadimastemJanuary 31, 2025 | markets.businessinsider.comKadimastem Shareholders Approved the Merger with NLS PharmaceuticsJanuary 31, 2025 | prnewswire.comNLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual MeetingJanuary 30, 2025 | prnewswire.comNLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl DependenceJanuary 28, 2025 | prnewswire.comNLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual DeclineJanuary 24, 2025 | msn.comKadimastem calls for Special Meeting of Shareholders to approve NLS mergerJanuary 17, 2025 | markets.businessinsider.comKadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLSJanuary 16, 2025 | prnewswire.comNLS Pharmaceutics Ltd. and Kadimastem Ltd.January 8, 2025 | prnewswire.comNLS Pharmaceutics, Kadimastem announce filing of F-4 Registration StatementDecember 31, 2024 | markets.businessinsider.comNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed MergerDecember 30, 2024 | tmcnet.comNLS Pharmaceutics Ltd. and Kadimastem Ltd.December 30, 2024 | prnewswire.comNLS Pharmaceutics and Kadimastem Advance Diabetes Treatment with FDA SubmissionDecember 20, 2024 | markets.businessinsider.comNLS Pharmaceutics Plans Capital Increase at Extraordinary Shareholders’ MeetingDecember 17, 2024 | markets.businessinsider.comNLS Pharmaceutics Offers New Investment OpportunitiesDecember 6, 2024 | markets.businessinsider.comNLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the MarketDecember 4, 2024 | prnewswire.comNLS Pharmaceutics AG Announces Share Capital ExpansionNovember 16, 2024 | markets.businessinsider.comKadimastem Ltd. Faces Financial UncertaintyNovember 13, 2024 | markets.businessinsider.comNLS Pharmaceutics Announces Strategic Capital RestructuringNovember 7, 2024 | markets.businessinsider.comNLS Pharmaceutics and Kadimastem Announce Strategic MergerNovember 6, 2024 | markets.businessinsider.comNLS Pharmaceutics (NASDAQ:NLSP) Stock, Short Interest ReportNovember 4, 2024 | benzinga.comNLS Pharmaceutics, Kadimastem enter definitive merger agreementNovember 4, 2024 | markets.businessinsider.comNLS Pharmaceutics Merges with Kadimastem for Strategic GrowthNovember 4, 2024 | markets.businessinsider.comWhat's Going On With NLS Pharmaceutics Shares Monday?November 4, 2024 | msn.comNLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm KadimastemNovember 4, 2024 | msn.comNLS Pharmaceutics Achieves Nasdaq Compliance MilestoneOctober 29, 2024 | markets.businessinsider.comNLS Pharmaceutics regains full compliance with Nasdaq listing rulesOctober 29, 2024 | markets.businessinsider.comNLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing RequirementsOctober 28, 2024 | finance.yahoo.comNLS Pharmaceutics secures patent in Japan for Mazindol EROctober 22, 2024 | markets.businessinsider.comNLS Pharmaceutics Sees Reduced Losses Amid Financial ChallengesOctober 20, 2024 | finance.yahoo.comWhy Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?July 29, 2024 | investorplace.comNLS Pharmaceutics to Absorb Kadimastem as Subsidiary After Agreeing to MergerJuly 29, 2024 | marketwatch.comKadimastem To Become Subsidiary Of NLS; Kadimastem Shareholders To Hold 85% Of Merged Company SharesJuly 29, 2024 | markets.businessinsider.comNLSP NLS Pharmaceutics AGJuly 26, 2024 | seekingalpha.comWhy Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?June 20, 2024 | investorplace.comWhy Is NLS Pharmaceutics (NLSP) Stock Up 163% Today?June 18, 2024 | investorplace.comNLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat ModelMay 28, 2024 | stockhouse.comNLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqMay 24, 2024 | finanznachrichten.deNLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqMay 24, 2024 | finance.yahoo.comNLS Pharmaceutics AG: NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct OfferingMarch 22, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces $1.75 Million Registered Direct OfferingMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering EventMarch 14, 2024 | finanznachrichten.de Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address NLSP Media Mentions By Week NLSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NLSP News Sentiment▼0.000.60▲Average Medical News Sentiment NLSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NLSP Articles This Week▼01▲NLSP Articles Average Week Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Q32 Bio News BioVie News Pluri News Bullfrog AI News Incannex Healthcare News Rallybio News ProMIS Neurosciences News CEL-SCI News Marinus Pharmaceuticals News Coeptis Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NLSP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
